E-Cigarettes: What’s Known, What’s Unknown.
... What’s known, what’s unknown. Tex Dent J. 2013 May; 130(5): 446-52Rankin KV Use and awareness of the e-cigarette, also referred to in the literature as an Electronic Nicotine Delivery Device, has dramatically increased since its introduction to the U.S.… Continue reading
Antiproliferative Activity of New Benzimidazole Derivatives.
... skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that… Continue reading
Defining a Clinically Meaningful Effect for the Design and Interpretation of Randomized Controlled Trials.
... Survey. Innov Clin Neurosci. 2013 5; 10(5-6 Suppl A): 20S-28SStewart M, Butler A, Alphs L, Chappell PB, Feltner DE, Lenderking WR, Mahableshwarkar AR, Makumi CW, Dubrava S Objective: The International Society for CNS Clinical Trials and Methodology Suicidal Ideation… Continue reading
Hepatoprotective and Antioxidant Effects of Saponarin, Isolated From Gypsophila Trichotoma Wend. on Paracetamol-Induced Liver Damage in Rats.
... PLGA-PEG-Fe3O4 could be an appropriate carrier for hydrophobic agents such as silibinin to improve their action in cancer therapy. HubMed – drug Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount. Surg Neurol… Continue reading
Analytical and Clinical Performance of the CDC Real Time RT-PCR Assay for Detection and Typing of Dengue Virus.
... Medina JF, Medina F, Colón C, Margolis H, Muñoz-Jordán JL Dengue is an acute illness caused by the positive-strand RNA dengue virus (DENV). There are four genetically distinct DENVs (DENV-1-4) that cause disease in tropical and subtropical countries. Most… Continue reading
Asean's 2015 Drug–Free Target 'Unrealistic'
... then herd thousands of drug users into compulsory treatment centres, ignoring evidence-based approaches, and despite a joint UN statement in 2012 calling for the closure of such centers, which are deemed costly with high relapse rates and a … Read… Continue reading
Selumetinib Shows Promise in Metastatic Uveal Melanoma.
... OF8 Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease.… Continue reading